Annotation Detail
Information
- Associated Genes
- STK11
- Associated Variants
-
STK11 LOSS
(
ENST00000326873.12 )
STK11 LOSS ( ENST00000326873.12 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Lkb1 (STK11) knockout mutant mice showed only mild response to combined treatment and very low response rates to docetaxel monotherapy compared to mice with Kras(G12D) alone or Kras(G12D) and Trp53 knockout. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1144
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5534
- Variant URL
- https://civic.genome.wustl.edu/links/variants/485
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Docetaxel,Selumetinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 22425996
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Docetaxel | Resitance or Non-Reponse | true |
| Selumetinib | Resitance or Non-Reponse | true |